Development and validation of an automated radiomic CT signature for detecting COVID-19
Abstract Background The coronavirus disease 2019 (COVID-19) outbreak has reached pandemic status. Drastic measures of social distancing are enforced in society and healthcare systems are being pushed to and over their limits.Objectives To develop a fully automatic framework to detect COVID-19 by applying AI to chest CT and evaluate validation performance.Methods In this retrospective multi-site study, a fully automated AI framework was developed to extract radiomics features from volumetric chest CT exams to learn the detection pattern of COVID-19 patients. We analysed the data from 181 RT-PCR confirmed COVID-19 patients as well as 1200 other non-COVID-19 control patients to build and assess the performance of the model. The datasets were collected from 2 different hospital sites of the CHU Liège, Belgium. Diagnostic performance was assessed by the area under the receiver operating characteristic curve (AUC), sensitivity and specificity.Results 1381 patients were included in this study. The average age was 64.4±15.8 and 63.8±14.4 years with a gender balance of 56% and 52% male in the COVID-19 and control group, respectively. The final curated dataset used for model construction and validation consisted of chest CT scans of 892 patients. The model sensitivity and specificity for detecting COVID-19 in the test set (training 80% and test 20% of patients) were 78.94% and 91.09%, respectively, with an AUC of 0.9398 (95% CI: 0.875–1). The negative predictive value of the algorithm was found to be larger than 97%.Conclusions Benchmarked against RT-PCR confirmed cases of COVID-19, our AI framework can accurately differentiate COVID-19 from routine clinical conditions in a fully automated fashion. Thus, providing rapid accurate diagnosis in patients suspected of COVID-19 infection, facilitating the timely implementation of isolation procedures and early intervention..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guiot, J. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.04.28.20082966 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI01775609X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI01775609X | ||
| 003 | DE-627 | ||
| 005 | 20240425104304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200504s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.04.28.20082966 |2 doi | |
| 035 | |a (DE-627)XBI01775609X | ||
| 035 | |a (biorXiv)10.1101/2020.04.28.20082966 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guiot, J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and validation of an automated radiomic CT signature for detecting COVID-19 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background The coronavirus disease 2019 (COVID-19) outbreak has reached pandemic status. Drastic measures of social distancing are enforced in society and healthcare systems are being pushed to and over their limits.Objectives To develop a fully automatic framework to detect COVID-19 by applying AI to chest CT and evaluate validation performance.Methods In this retrospective multi-site study, a fully automated AI framework was developed to extract radiomics features from volumetric chest CT exams to learn the detection pattern of COVID-19 patients. We analysed the data from 181 RT-PCR confirmed COVID-19 patients as well as 1200 other non-COVID-19 control patients to build and assess the performance of the model. The datasets were collected from 2 different hospital sites of the CHU Liège, Belgium. Diagnostic performance was assessed by the area under the receiver operating characteristic curve (AUC), sensitivity and specificity.Results 1381 patients were included in this study. The average age was 64.4±15.8 and 63.8±14.4 years with a gender balance of 56% and 52% male in the COVID-19 and control group, respectively. The final curated dataset used for model construction and validation consisted of chest CT scans of 892 patients. The model sensitivity and specificity for detecting COVID-19 in the test set (training 80% and test 20% of patients) were 78.94% and 91.09%, respectively, with an AUC of 0.9398 (95% CI: 0.875–1). The negative predictive value of the algorithm was found to be larger than 97%.Conclusions Benchmarked against RT-PCR confirmed cases of COVID-19, our AI framework can accurately differentiate COVID-19 from routine clinical conditions in a fully automated fashion. Thus, providing rapid accurate diagnosis in patients suspected of COVID-19 infection, facilitating the timely implementation of isolation procedures and early intervention. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Vaidyanathan, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Deprez, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Zerka, F. |e verfasserin |4 aut | |
| 700 | 1 | |a Danthine, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Frix, A.N. |e verfasserin |4 aut | |
| 700 | 1 | |a Thys, M. |e verfasserin |4 aut | |
| 700 | 1 | |a Henket, M. |e verfasserin |4 aut | |
| 700 | 1 | |a Canivet, G. |e verfasserin |4 aut | |
| 700 | 1 | |a Mathieu, S. |e verfasserin |4 aut | |
| 700 | 1 | |a Eftaxia, E. |e verfasserin |4 aut | |
| 700 | 1 | |a Lambin, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Tsoutzidis, N. |e verfasserin |4 aut | |
| 700 | 1 | |a Miraglio, B. |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, S. |e verfasserin |4 aut | |
| 700 | 1 | |a Moutschen, M. |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, R. |e verfasserin |4 aut | |
| 700 | 1 | |a Meunier, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Vos, W. |e verfasserin |4 aut | |
| 700 | 1 | |a Leijenaar, R.T.H. |e verfasserin |4 aut | |
| 700 | 1 | |a Lovinfosse, P. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/diagnostics11010041 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.04.28.20082966 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||